ATE526985T1 - Aus interleukin-1-beta abgeleitetes peptid und therapeutische verwendung davon - Google Patents

Aus interleukin-1-beta abgeleitetes peptid und therapeutische verwendung davon

Info

Publication number
ATE526985T1
ATE526985T1 AT03740584T AT03740584T ATE526985T1 AT E526985 T1 ATE526985 T1 AT E526985T1 AT 03740584 T AT03740584 T AT 03740584T AT 03740584 T AT03740584 T AT 03740584T AT E526985 T1 ATE526985 T1 AT E526985T1
Authority
AT
Austria
Prior art keywords
gln
cytokine
beta
microg
residues
Prior art date
Application number
AT03740584T
Other languages
German (de)
English (en)
Inventor
Jean-Francois Zagury
Original Assignee
Vaxconsulting
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxconsulting filed Critical Vaxconsulting
Application granted granted Critical
Publication of ATE526985T1 publication Critical patent/ATE526985T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5409—IL-5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03740584T 2002-04-10 2003-04-09 Aus interleukin-1-beta abgeleitetes peptid und therapeutische verwendung davon ATE526985T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0204464A FR2838444B1 (fr) 2002-04-10 2002-04-10 Nouveaux peptides et leur application en therapeutique
PCT/FR2003/001120 WO2003084979A2 (fr) 2002-04-10 2003-04-09 Peptides et leur application en therapeutique

Publications (1)

Publication Number Publication Date
ATE526985T1 true ATE526985T1 (de) 2011-10-15

Family

ID=28459716

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03740584T ATE526985T1 (de) 2002-04-10 2003-04-09 Aus interleukin-1-beta abgeleitetes peptid und therapeutische verwendung davon

Country Status (20)

Country Link
US (6) US7393523B2 (https=)
EP (3) EP2314311B1 (https=)
JP (1) JP2005530723A (https=)
KR (1) KR101101004B1 (https=)
CN (1) CN1649898A (https=)
AT (1) ATE526985T1 (https=)
AU (1) AU2003260031B2 (https=)
CA (1) CA2480996C (https=)
DK (1) DK2314311T3 (https=)
ES (2) ES2550030T3 (https=)
FR (1) FR2838444B1 (https=)
IL (1) IL164429A0 (https=)
MA (1) MA27191A1 (https=)
MX (1) MXPA04009841A (https=)
NZ (1) NZ536351A (https=)
RU (1) RU2326125C2 (https=)
SI (1) SI2314311T1 (https=)
TN (1) TNSN04200A1 (https=)
WO (1) WO2003084979A2 (https=)
ZA (1) ZA200408451B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7422743B2 (en) * 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
FR2859725B1 (fr) * 2003-09-16 2006-03-10 Neovacs Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
AU2005220156B2 (en) * 2004-02-27 2011-06-02 Vaxconsulting Peptides of IL1 beta and TNF alpha and method of treatment using same
NZ566971A (en) 2005-09-28 2011-06-30 Cytos Biotechnology Ag Vaccine containing a virus like particle linked with an interleukin-1 molecule
NZ592943A (en) * 2008-11-17 2012-09-28 Uinv Kobenhavns Il-4-derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases
EP2480251B1 (en) 2009-09-21 2025-12-03 Peptinov Carrier conjugates of il-23-peptides and their induced antibodies
WO2011143280A2 (en) 2010-05-11 2011-11-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide-based inhibitor of interleukin-10 or interferon-gamma signaling
WO2013140785A1 (ja) * 2012-03-18 2013-09-26 国立大学法人九州大学 疾患サンプル分析装置、分析システム及び分析方法
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
US10576131B2 (en) * 2015-06-03 2020-03-03 Affiris Ag IL-23-p19 vaccines
EP3696547B1 (en) * 2017-10-13 2025-08-13 Nibec Co., Ltd. Grp78-derived peptide for identifying high-efficiency stem cells
EP3966230A1 (en) * 2019-05-10 2022-03-16 Bimyo GmbH Bnip3 peptides for treatment of reperfusion injury
EP4486389A1 (en) 2022-02-28 2025-01-08 Tridem Bioscience GmbH & Co KG A conjugate comprising at least a beta-glucan

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772685A (en) * 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US5013824A (en) * 1985-11-19 1991-05-07 Schering Corporation Human interleukin-4 peptides and conjugates thereof
DE3841761A1 (de) * 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
ATE136906T1 (de) * 1989-12-20 1996-05-15 Schering Corp Antikörperantagonisten gegen humanes interleukin- 4
EP0521918A4 (en) * 1990-03-19 1993-05-05 Peptide Technology Ltd Anti-tumour peptides
FR2677654B1 (fr) * 1991-06-17 1995-11-17 Pasteur Merieux Serums Vacc Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv.
US6117974A (en) * 1991-10-02 2000-09-12 Peptor Limited Libraries of backbone-cyclized peptidomimetics
US5494662A (en) * 1992-04-27 1996-02-27 Ono Pharmaceutical Co., Ltd. Stimulator for bone formation
AU4554493A (en) * 1992-07-07 1994-01-31 Eleanor N. Fish Interferon receptor binding peptides
US5770191A (en) * 1995-05-24 1998-06-23 University Of Florida Active C-terminal peptides of interferon--gamma and their use
US5994292A (en) * 1995-05-31 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
IT1277926B1 (it) * 1995-09-01 1997-11-12 Angeletti P Ist Richerche Bio Uso di muteine di citochine naturali come immunogeni per la preparazione di composizioni farmaceutiche per curare o prevenire
JP2001511649A (ja) * 1997-02-07 2001-08-14 トーマス・ジェファーソン・ユニバーシティ サイトカインレセプターガンマ鎖のペプチド模倣物
IT1291353B1 (it) * 1997-05-12 1999-01-07 San Raffaele Centro Fond Peptidi con attivita' antivirale
AU5201399A (en) * 1997-09-30 1999-10-18 Pharmacia & Upjohn Company Tnf-related death ligand
AU773029B2 (en) * 1999-02-08 2004-05-13 Medvet Science Pty. Ltd. Cytokine-binding domain
KR20010102556A (ko) * 1999-03-11 2001-11-15 추후제출 암 및 과증식성 장애의 치료 조성물 및 치료방법
US7129072B1 (en) * 1999-08-30 2006-10-31 New York University Crystal of fibroblast growth factor receptor 1 in complex with fibroblast growth factor
US6420346B1 (en) * 2000-02-07 2002-07-16 Rappaport Family Institute For Research In The Medical Sciences Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis
WO2002044197A2 (en) * 2000-12-01 2002-06-06 Fish Eleanor N Cytokine receptor binding peptides
US20030166589A1 (en) * 2001-06-05 2003-09-04 Nathan Karin Method and pharmaceutical composition for the treatment of multiple sclerosis

Also Published As

Publication number Publication date
EP1492814B1 (fr) 2011-10-05
DK2314311T3 (en) 2015-10-12
WO2003084979A3 (fr) 2004-04-08
EP2314311A3 (fr) 2011-08-17
EP1492814A2 (fr) 2005-01-05
US20080260689A1 (en) 2008-10-23
CN1649898A (zh) 2005-08-03
EP2314311A2 (fr) 2011-04-27
US20120121627A1 (en) 2012-05-17
AU2003260031A1 (en) 2003-10-20
TNSN04200A1 (fr) 2007-03-12
KR101101004B1 (ko) 2011-12-29
US8277792B2 (en) 2012-10-02
KR20040108709A (ko) 2004-12-24
EP2314311B1 (fr) 2015-07-15
CA2480996A1 (fr) 2003-10-16
ES2375053T3 (es) 2012-02-24
ES2550030T3 (es) 2015-11-04
IL164429A0 (en) 2005-12-18
EP2314312A2 (fr) 2011-04-27
WO2003084979A2 (fr) 2003-10-16
US20110171169A1 (en) 2011-07-14
RU2004132871A (ru) 2005-09-20
NZ536351A (en) 2007-03-30
US7393523B2 (en) 2008-07-01
US20120321652A1 (en) 2012-12-20
MA27191A1 (fr) 2005-01-03
ZA200408451B (en) 2006-01-25
SI2314311T1 (sl) 2015-12-31
FR2838444B1 (fr) 2016-01-01
US8147819B2 (en) 2012-04-03
JP2005530723A (ja) 2005-10-13
US7641895B2 (en) 2010-01-05
US7892529B2 (en) 2011-02-22
EP2314312A3 (fr) 2011-08-31
CA2480996C (fr) 2016-06-21
US20060241286A1 (en) 2006-10-26
US20100150957A1 (en) 2010-06-17
AU2003260031B2 (en) 2009-10-29
US8529881B2 (en) 2013-09-10
FR2838444A1 (fr) 2003-10-17
RU2326125C2 (ru) 2008-06-10
MXPA04009841A (es) 2005-06-17

Similar Documents

Publication Publication Date Title
ATE526985T1 (de) Aus interleukin-1-beta abgeleitetes peptid und therapeutische verwendung davon
DE69408342D1 (de) Die induktion der antikörperantwort gegen eigene proteine mit hilfe fremder t-zellepitope
BR0209685A (pt) Derivado de um peptìdeo insulinotrópico e sais farmaceuticamente aceitáveis produzidos a partir do mesmo, método de produção de derivado de peptìdeo insulinotrópico e uso de um derivado de peptìdeo insulinotrópico e de sais farmaceuticamente aceitáveis
ATE258188T1 (de) Retro-, inverso-, und retro-inverso synthetische peptidanaloge
ATE258444T1 (de) Therapeutische chemokine rezeptor antagonisten
DE3924746A1 (de) Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
WO2002004499A1 (en) Chemokine receptor modulators, production and use
EA200501550A1 (ru) СВЯЗАННЫЕ С МАТРИЦЕЙ ПЕПТИДОМИМЕТИКИ β-ШПИЛЕЧНОЙ СТРУКТУРЫ С АКТИВНОСТЬЮ АНТАГОНИСТОВ CXCR4
ATE238065T1 (de) Peptide zur verwendung in impfung und anregung von antikörperbildung gegen menschliches immunschwäche virus
DE50309916D1 (de) Verwendung eines lipopeptids oder lipoproteins als adjuvans bei therapeutischer oder prophylaktischer vakzinierung
DK0413383T3 (da) Mutanter af humant interleukin-3.
JP2005530723A5 (https=)
Vichier-Guerre et al. Synthesis and immunological evaluation of an antitumor neoglycopeptide vaccine bearing a novel homoserine Tn antigen
Jeannin et al. Immunogenecity and antigenicity of synthetic peptides derived from the mite allergen Der p I
JP7220489B2 (ja) 炎症性疾患および疼痛を治療するためのペプチドを含有する薬剤
ATE422503T1 (de) Rekombinante polypeptide aus mycoplasma und impfstoffe
CA2158748A1 (en) Botulinum toxin polypeptides and their use as vaccine enhancing agents
CN100540050C (zh) 含有白细胞介素-15(il-15)的疫苗组合物
US20040077835A1 (en) Chemokine receptor modulators, production and use
Herzbeck et al. Functional and Molecular Characterization of a Monoclonal Antibody against the 165–186 Peptide of Human 1β
CN114621329A (zh) 一种t细胞表位肽复合物
DE3886443D1 (de) Menschliche Rhinoviruspeptide.
US20230131650A1 (en) Immunogenic conjugate intended to induce an immune response directed against interleukin-6
Babakhin et al. 185 Immunomodulating activity of the extract from high mycelium fungus polyporus squamosus
DE69123252D1 (de) Kreuzreaktive immunisierung gegen influenza

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties